Your browser doesn't support javascript.
loading
Manganese-Enhanced MRI of the Brain in Healthy Volunteers.
Sudarshana, D M; Nair, G; Dwyer, J T; Dewey, B; Steele, S U; Suto, D J; Wu, T; Berkowitz, B A; Koretsky, A P; Cortese, I C M; Reich, D S.
Afiliação
  • Sudarshana DM; From the National Institute of Neurological Disorders and Stroke (D.M.S., G.N., J.T.D., B.D., S.U.S., D.J.S., T.W., A.P.K., I.C.M.C., D.S.R.), National Institutes of Health, Bethesda, Maryland.
  • Nair G; Cleveland Clinic Lerner College of Medicine of Case Western Reserve University (D.M.S.), Cleveland, Ohio.
  • Dwyer JT; From the National Institute of Neurological Disorders and Stroke (D.M.S., G.N., J.T.D., B.D., S.U.S., D.J.S., T.W., A.P.K., I.C.M.C., D.S.R.), National Institutes of Health, Bethesda, Maryland.
  • Dewey B; From the National Institute of Neurological Disorders and Stroke (D.M.S., G.N., J.T.D., B.D., S.U.S., D.J.S., T.W., A.P.K., I.C.M.C., D.S.R.), National Institutes of Health, Bethesda, Maryland.
  • Steele SU; From the National Institute of Neurological Disorders and Stroke (D.M.S., G.N., J.T.D., B.D., S.U.S., D.J.S., T.W., A.P.K., I.C.M.C., D.S.R.), National Institutes of Health, Bethesda, Maryland.
  • Suto DJ; From the National Institute of Neurological Disorders and Stroke (D.M.S., G.N., J.T.D., B.D., S.U.S., D.J.S., T.W., A.P.K., I.C.M.C., D.S.R.), National Institutes of Health, Bethesda, Maryland.
  • Wu T; From the National Institute of Neurological Disorders and Stroke (D.M.S., G.N., J.T.D., B.D., S.U.S., D.J.S., T.W., A.P.K., I.C.M.C., D.S.R.), National Institutes of Health, Bethesda, Maryland.
  • Berkowitz BA; From the National Institute of Neurological Disorders and Stroke (D.M.S., G.N., J.T.D., B.D., S.U.S., D.J.S., T.W., A.P.K., I.C.M.C., D.S.R.), National Institutes of Health, Bethesda, Maryland.
  • Koretsky AP; Department of Ophthalmology (B.A.B.), Visual and Anatomical Sciences, Wayne State University School of Medicine, Detroit, Michigan.
  • Cortese ICM; From the National Institute of Neurological Disorders and Stroke (D.M.S., G.N., J.T.D., B.D., S.U.S., D.J.S., T.W., A.P.K., I.C.M.C., D.S.R.), National Institutes of Health, Bethesda, Maryland.
  • Reich DS; From the National Institute of Neurological Disorders and Stroke (D.M.S., G.N., J.T.D., B.D., S.U.S., D.J.S., T.W., A.P.K., I.C.M.C., D.S.R.), National Institutes of Health, Bethesda, Maryland.
AJNR Am J Neuroradiol ; 40(8): 1309-1316, 2019 08.
Article em En | MEDLINE | ID: mdl-31371354
ABSTRACT
BACKGROUND AND

PURPOSE:

The manganese ion is used as an intracellular MR imaging contrast agent to study neuronal function in animal models, but it remains unclear whether manganese-enhanced MR imaging can be similarly useful in humans. Using mangafodipir (Teslascan, a chelated manganese-based contrast agent that is FDA-approved), we evaluated the dynamics of manganese enhancement of the brain and glandular structures in the rostral head and neck in healthy volunteers. MATERIALS AND

METHODS:

We administered mangafodipir intravenously at a rate of 1 mL/minute for a total dose of 5 µmol/kg body weight. Nine healthy adult volunteers (6 men/3 women; median age, 43 years) completed baseline history and physical examination, 3T MR imaging, and blood work. MR imaging also followed mangafodipir administration at various time points from immediate to 7 days, with delayed scans at 1-3 months.

RESULTS:

The choroid plexus and anterior pituitary gland enhanced within 10 minutes of infusion, with enhancement persisting up to 7 and 30 days, respectively. Exocrine (parotid, submandibular, sublingual, and lacrimal) glands also enhanced avidly as early as 1 hour postadministration, generally resolving by 1 month; 3 volunteers had residual exocrine gland enhancement, which resolved by 2 months in 1 and by 3 months in the other 2. Mangafodipir did not affect clinical parameters, laboratory values, or T1-weighted signal in the basal ganglia.

CONCLUSIONS:

Manganese ions released from mangafodipir successfully enable noninvasive visualization of intra- and extracranial structures that lie outside the blood-brain barrier without adverse clinical effects, setting the stage for future neuroradiologic investigation in disease.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Fosfato de Piridoxal / Imageamento por Ressonância Magnética / Ácido Edético / Meios de Contraste Tipo de estudo: Prognostic_studies Limite: Adult / Female / Humans / Male Idioma: En Revista: AJNR Am J Neuroradiol Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Fosfato de Piridoxal / Imageamento por Ressonância Magnética / Ácido Edético / Meios de Contraste Tipo de estudo: Prognostic_studies Limite: Adult / Female / Humans / Male Idioma: En Revista: AJNR Am J Neuroradiol Ano de publicação: 2019 Tipo de documento: Article